Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis

Thrift, Aaron P.

doi:10.1016/j.cgh.2015.03.028

Cited by 9 publications

(6 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…nonsteroidal anti-inflammatory drugs or statins were not co-investigated. 40 Locoregional controle rate was not assessed because the lack of objective and accurate information of the anastomotic site e.g. endoscopy and biopsy.…”

Section: Discussionmentioning

confidence: 99%

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Voorde

Janssen

Larue

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Voorde

Janssen

Larue

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Compared to ESCC, EAC is relatively common in Western countries. Patients with EAC exhibit similar features to those of liver cancer, lung cancer, and pancreatic cancer; the five-year overall survival rate for EAC is only 16%, and the median survival time is less than one year 5 , 6 . EAC is usually associated with obesity and gastroesophageal reflux disease 7 .…”

Section: Introductionmentioning

confidence: 95%

Advances and challenges in the treatment of esophageal cancer

Liu

et al. 2021

Acta Pharmaceutica Sinica B

156

113

View full text Add to dashboard Cite

Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries. The currently available treatment strategies for EC include surgery, chemotherapy, radiation therapy, molecular targeted therapy, and combinations thereof. However, the prognosis remains poor, and the overall five-year survival rate is very low. Therefore, achieving the goal of effective treatment remains challenging. In this review, we discuss the latest developments in chemotherapy and molecular targeted therapy for EC, and comprehensively analyze the application prospects and existing problems of immunotherapy. Collectively, this review aims to provide a better understanding of the currently available drugs through in-depth analysis, promote the development of new therapeutic agents, and eventually improve the treatment outcomes of patients with EC.

show abstract

“…Over the last few decades there has been a marked increase in the incidence of oesophageal adenocarcinoma (OAC) throughout North America and Europe at a rate exceeding that for any other solid tumour 1 .…”

Section: Introductionmentioning

confidence: 99%

“…In the UK, in 2010, 26.1% of adults were reported to be obese, one of the highest rates in Europe, and 4.3% were estimated to have T2D 8 . Although other factors such as genetic predisposition may contribute to obesity, in general, increased caloric intake and decreased physical activity have been identified as primary causes for the observed trends 1 , 9 . Literature suggests that visceral abdominal fat is associated with an increased risk for T2D, ischaemic heart disease and malignancies including colorectal cancer 10 , 11 .…”

Section: Introductionmentioning

confidence: 99%

Role of body composition and metabolic profile in Barrett’s oesophagus and progression to cancer

Cheung

Fini

et al. 2016

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Background and aimsThe aim of this study was to evaluate the risk for Barrett’s oesophagus (BE) on the basis of body composition, metabolic pathways, adipokines and metabolic syndrome (MS), as well as their role in cancer progression.MethodsIn patients with and without BE at gastroscopy, data on MS, BMI, waist/hip ratio for abdominal obesity (AO) and body fat percentage by bioimpedance were obtained. Fasting plasma glucose, insulin, HbA1c, lipid, serum adiponectin and leptin levels were measured. The homoeostasis model assessment (HOMA-IR) was used to estimate insulin resistance. Histological findings for BE were correlated with the above parameters. Risk factors for BE identified using univariate analysis were entered into a multivariate logistic regression analysis.ResultsA total of 250 patients and 224 controls (F/M: 189/285, mean age 58.08±15.51 years) were enroled. In the BE and control groups, 39.6 versus 31.3% were overweight, 32 versus 22.8% were obese, 75.6 versus 51.3% had AO, and 28.1 versus 18.9% were metabolically obese, respectively. AO [odds ratio (OR) 3.08], increased body fat percentage (OR 2.29), and higher BMI (overweight: OR 2.04; obese: OR 2.26) were significantly associated with BE. A positive trend was found in Normal Weight Obese Syndrome (OR 1.69). MS was associated with BE (overweight: OR 3.05; obese: OR 5.2; AO: OR 8.08). Insulin levels (P=0.05) and HOMA-IR (P<0.001) were higher in BE. AO was the only independent risk factor associated with BE (OR 1.65; P=0.02) and high-grade dysplasia (OR 2.44) on multivariate analysis.ConclusionAO was strongly associated with BE and dysplasia. BE was associated with MS and higher insulin/HOMA-IR, suggesting the activation of specific metabolic pathways in patients with altered body composition.

show abstract

Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis

Cited by 9 publications

References 107 publications

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Advances and challenges in the treatment of esophageal cancer

Role of body composition and metabolic profile in Barrett’s oesophagus and progression to cancer

Contact Info

Product

Resources

About